Good afternoon, and welcome to the Tarsus Pharmaceuticals Q3 2023 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. Please begin. Thank you. Before we begin, I encourage everyone to go to the investors section of the Tarsus website to view the earnings release and related financial tables we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Mottiwala, our Chief Commercial Officer, and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer. I'd like to draw your attention to slide three, which contains our forward-looking, forward-looking statement. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. With that, I will turn the call over to Bobby. Bobby? Thank you, Dave, and thank you all for joining us for our first-ever earnings call and our first opportunity to speak with you since the highly anticipated launch of XDEMVY, the only FDA-approved treatment for Demodex blepharitis. We are off to a great start, and I am pleased to share our progress with you today. Demodex blepharitis is a pervasive and damaging eyelid disease that affects approximately 25 million Americans. Of these, more than 7 million are seeking treatment for a complementary eye condition. Double-clicking on that number, more than 1.5 million people have already been diagnosed with Demodex blepharitis and are highly motivated to find an effective treatment. As anticipated, this is the patient segment driving strong initial demand, and as the XDEMVY launch progresses, we expect to expand further into that group of 7 million patients. XDEMVY was approved a month ahead of its scheduled PDUFA date, and as planned, we made sure it was available to patients within a month of approval. Today, I am proud to report that we are delivering on the expectations we set for ourselves and for the launch of XDEMVY. Specifically, in the Q3, we generated $1.7 million in net sales, and we delivered XDEMVY to more than 1,700 patients eagerly awaiting a new solution for Demodex blepharitis. These results speak to the two key advantages that make XDEMVY launch unique. One, XDEMVY is the first and only FDA-approved medicine to treat Demodex blepharitis, which has enabled us to build an entirely new market focused on eyelid health. Two, XDEMVY offers a defined course of treatment that delivers strong and durable outcomes and provides value to payers, eye care providers, and patients. You will hear more about our progress on both fronts later in this call. For those of you who are not familiar with Demodex blepharitis, it's caused by an infestation of Demodex mites, the most common parasite found on humans. Patients with this disease need treatment. They can experience ocular redness, dryness, discomfort, missing or misdirected eyelashes, itching, and burning. Importantly, the cost, quality of life burden, and psychosocial effects are significant. Patient impact ranges from the inability to wear makeup to functional issues such as driving, difficulty driving at night. And in the most advanced stages of disease, there may also be corneal involvement, which can negatively impact a patient's vision. Turning to the next slide, you'll see exactly what I mean. This is a photo gallery of patients who have been suffering for years with Demodex blepharitis and prior to their treatment with XDEMVY. I'd like to draw your attention to one image in particular, the one in the upper right-hand corner. This is Lucas. He's a very active gentleman, retired chemical engineer. In addition to keeping up with his eight grandchildren, he is also a competitive fencer. I had the great chance to meet Lucas last week. He shared with me that his watery eyes, irritation, and blurred vision not only made it hard for him to participate in competitive fencing tournaments but also made it hard to read the newspaper every day. As you can see in this photo, his eyelashes are crusted with collarettes, the telltale signs of Demodex blepharitis. Fast forward five weeks, a little less than a full course of therapy with XDEMVY complete. A stark contrast, no collarettes, no redness. But what stands out most to me is the impact XDEMVY has had on his daily activities. This is only one of the many similar stories we heard and similar photos we saw from eye care providers, or ECPs for short, during the recent American Academy of Optometry and American Academy of Ophthalmology conferences. So when I say I'm confident about the blockbuster potential of XDEMVY, not just because of the $1.7 million in net product sales we reported for our first five weeks of launch, it's also because of the impact we are having on patients like Lucas. Again, we are off to a great start. The momentum we're already generating in these early days is proof of the value proposition of this category-creating product, our extensive disease educational efforts, and the seasoned leadership of our commercial organization, led by our Chief Commercial Officer, Aziz Mottiwala. Finally, I know the XDEMVY launch is top of mind, but I want to close by reminding everyone of the potential of our robust pipeline and the near-term data readouts that will be important for our long-term growth, all of which will be addressed by Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer, later in the call. I will now turn the call over to Aziz for more detail on our launch progress. Thanks, Bobby. As the initial launch metrics demonstrate, the enthusiasm for XDEMVY is truly remarkable. I've worked in the eye care industry for more than 20 years, and I've never seen this kind of early response, which I believe speaks to our unique and differentiated approach. In July, we shared our strategic and deliberate launch plan, and we are executing successfully on this plan. We have a driven, best-in-class team comprised of eye care experts and product launch veterans that are exceeding expectations on a daily basis. So far, our near-term accomplishments are delivering a solid foundation for the long-term expectations we have set for ourselves and for XDEMVY. That said, launching a first-in-class therapeutic is a marathon and not a sprint, and we are primed for a steady launch trajectory as we continue to build demand and secure high-value payer contracts. Category creation requires both substantial disease education and behavioral change. Diagnosing Demodex blepharitis is a simple task, as it just requires patients to look down during every eye exam and looking for collarettes, the sure sign of disease. As simple as it sounds, not every eye doctor is doing it, at least not yet. We recognize that a shift in behavior like this will take time, which is why we initiated disease state education campaigns for every eye care provider, as well as for patients well in advance of approval. We've now transitioned our efforts to Mite Over Mites, a complementary branded campaign that highlights the benefits of XDEMVY. As a result, recent market research indicates that nearly 70% of ECPs say they recognize the importance of screening for collarettes in every eye exam, and more than 90% of ECPs indicate intent to prescribe XDEMVY. That is truly a remarkable number. And what it says to me is that ECPs understand both the importance of treating this disease and the value that XDEMVY brings to their patients. This is further bolstered by the recent addition of XDEMVY to the American Academy of Ophthalmology's practice guidelines as the first and only FDA-approved treatment for Demodex blepharitis. We've also been highly successful in our differentiated approach to distribution, reimbursement, and patient access. Due to the unique high-value proposition of XDEMVY, we are already seeing initial non-contracted coverage that has resulted in better-than-expected gross-to-net discounts of 73%. It's a very encouraging metric for us, but I also want to caution that as more prescriptions start to come through their systems, payers may put more short-term and onerous prior authorizations in place until we can work through our ongoing contract negotiations. That said, based on our ongoing discussions with all the top payers, we still expect broad commercial coverage to build throughout 2024, and Medicare coverage to come online in 2025. Before I turn the call over to Jeff, I want to acknowledge our sales force, which has done a remarkable job of generating the initial demand for XDEMVY. They have already called on 80% of our top 400 decile prescribers, who, in the vast majority of cases, have been called on multiple times. As a result of these efforts and launch to date, more than 2,000 ECPs have started patients on XDEMVY, and nearly half of those ECPs are repeat prescribers. We're also seeing a positive trend in new ECPs writing every day. Now, when we look specifically at the Q3 results, we're pleased to report that approximately 1,700 bottles of XDEMVY were delivered to patients, and we recognized better-than-anticipated gross-to-net discounts of 73%. This encouraging first quarter after launch says to me that we have established a solid foundation for ongoing momentum that gives us great confidence in the potential of XDEMVY. I'll now turn the call over to Jeff Farrow for additional commentary on our financials and our pipeline. Jeff? Thanks, Aziz. I've been lucky enough to have been part of several companies who have brought innovative new solutions to patients in need. Based on that experience, I believe Tarsus is on the cusp of delivering blockbuster potential in an entirely new category of eye care. As Bobby noted, we had an exciting Q3, marked by $1.7 million in net product sales. We also completed an equity raise of nearly $100 million that will be used to support the ongoing launch of XDEMVY and other strategic priorities. As a reminder, we recognize revenue when we ship XDEMVY from our warehouse to the distributors, not just on bottles received by the patients. Looking forward, we are very encouraged by the meaningful numbers of bottles dispensed so far in the fourth quarter. But as we are still in the early days of an uncharted new launch, I wanted to highlight the potential fluctuations in both demand and gross-to-net discounts we might see in the future due to prescribers being out of the office for the American Academy of Ophthalmology and Optometry conferences, multiple holidays in the fourth quarter, potential short-term and more challenging prior authorization changes that payers may implement while we work to finalize contracts. Turning now to our pipeline, I'm pleased to provide an update on the multiple near-term phase 2 data readouts we anticipate in the coming months. Beyond XDEMVY, we are continuing to advance three novel therapeutics that target the root cause of the disease. All three are based on lotilaner, the same active ingredient in XDEMVY, providing us with a pipeline and a product. We remain on track to report top-line data from our Meibomian gland disease study by year-end, and top-line data from our rosacea study in the first quarter of 2024. Due to additional time required to fully enroll our Lyme disease prevention study, we now expect to report top-line results in the first quarter of 2024. Again, great progress here and the potential to continue building long-term value for the company and our shareholders. Finally, as you may have noted, earlier today, we filed a shelf registration statement in the amount of $300 million. This is merely a good housekeeping measure for Tarsus, and we have no immediate plans for financing. I also want to take this opportunity to note that the potential $2.5 million milestone we have with LianBio is now likely to be recognized in the first half of 2024. I will close by saying we remain well capitalized with approximately $247 million in cash at the end of Q3. Based on our current plan, this provides sufficient capital to support the ongoing launch of XDEMVY and the advancement of our clinical pipeline programs. With that, I will turn the call back to Bobby. Thank you, Jeff. As you heard today, this is an incredibly important and exciting time for our company. With the launch of XDEMVY, Tarsus is well on its way to becoming an eye care leader with the potential to deliver multiple therapies from our category-creating pipeline. Operator, please open the line for questions. Thank you. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. One moment for our first question. Our first question comes from Jason Gerberry of Bank of America. Hey, guys. Thanks for taking my questions. A couple for me. Y our comments in the PR about 1,700 bottles, that pretty closely lines up with the IQVIA data. J ust curious your thoughts on, on data reliability with IQVIA relative to Symphony, and if IQVIA is ultimately perhaps, like, the better data source for tracking here. And then, just your latest thoughts on the role, between optometrists and ophthalmologists. I t looks like I think you guys kind of had communicated this would be like kind of a 50/50 split, but it looks like ODs are about 62% of scripts so far. C urious if based on early observations, maybe, you know, how you're thinking about the optometrists, playing maybe a bigger role here. Hey, Jason, it's Aziz. I'm happy to answer those for you. So when we think about the syndicated data like IQVIA or Symphony, I think a couple of things to keep in mind here. One is we have a very unique distribution network with four focused pharmacies, and secondly, it's very early in the launch. Those two things really yield that these audits are a little bit more directional at best in early days. I'd say in more recent weeks, where they're looking better is just the trend and trajectory, but on a week-to-week basis, we see a lot of fluctuations in what they're reporting versus what we see here internally. We've been giving them a lot of the data feeds, so we anticipate as the weeks go on, that those data feeds will get more and more accurate. But I think for now, I would tell you that really focusing on the trajectory and the trend versus the week-to-week numbers, because you're going to see some fluctuations in their projections. Our goal is to just focus on driving volumes, and as the volumes increase, those will sort of align better over time. To your second question around the split across specialties, we're seeing great feedback from both ophthalmology and optometry. We reported over 2,000 doctors to date have gotten patients on therapy, and that is coming from a mix of both, as you mentioned. I think near term, we are seeing a slight slant towards optometry, but I think over the long haul, it, it'll start to even out. You'll see an equal contribution from both ophthalmologists and optometry. You know, maybe at most, it goes to 55 optometry, but we do anticipate that balancing out a little bit more over time. Okay. Thanks a lot. Thank you. One moment for our next question. Our next question comes from Tim, Tim Lugo of William Blair. Hey, guys, this is Lachlan on for Tim. Thanks for taking the question. At AAO, we heard a lot of discussion, you know, not necessarily from doctors, but other companies in the field around your pricing. So I was just wondering if you can discuss, you know, the initial feedback you've had, you know, been hearing there, particularly from payers. And then second, can you maybe just talk about how the ECP education has been going around, you know, Demodex mites leading to blepharitis and how that's been received with eye care professionals? And do you have any sense of kind of how many have incorporated, you know, looking for it into their existing practice? Yeah. Hey, thanks for the question. It's Aziz again. O n the first one around price, I think, we were very thoughtful and purposeful when we thought about the pricing for XDEMVY, really reflecting the value proposition the product brings. It's one course of therapy for six weeks. Gets great outcomes across multiple measures of disease, and it's the first and only approved product for the disease. All those things combined lead to a great value prop for physicians, patients, and payers. T he feedback we've gotten has been very reasonable on that. I think that's reflected in some of the non-contracted coverage we're seeing here in early days, and that's reflected in the better-than-expected gross- to- net discount. P ayers are covering this. We're having ongoing discussions with all the payers, and we're not seeing a lot of pushback there. Of course, those are all negotiations, and they're active negotiations, but I, I think, the payers do recognize the value proposition XDEMVY brings. They do acknowledge the unique aspect of the drug and the fact that it's the first and only. W e feel really good about that and, and stay committed to the idea of building commercial coverage through 2024 and having Part D come in on 2025. And then when it comes to education, this has been a focus of ours even prior to the launch. We had multiple campaigns, educating the physicians and patients on the disease. Our disease campaign was essentially, yes, having physicians screen for the disease by having patients look down. We're seeing that momentum continue to build now that the product is approved. As we stated in our prepared comments, 70% of doctors we survey say that it's important to look for collarettes, and furthermore, we know that if they're looking for collarettes, they understand that collarettes are pathognomonic for Demodex blepharitis. T hey are making the link. I think in early days, it's still important to build that habit and make it a routine in every exam, and that's our focus going forward, right? You can see the sales force and our medical affairs team are continuing to educate on disease. The sales force is out there linking the disease to the benefits of the product, and that's gonna be a continued focus for us, right? We're building a new category. It will take some time, but we are seeing great momentum there. I just want to add to that, Aziz. This is Bobby Azamian. I've been in the field, as has our executive team, roughly monthly, and, I've seen that education take place. I was once in a very urban environment and next in a more suburban environment. And just as Aziz said, you see some doctors that are immediately prescribing and doing multiples, and then you see some doctors that need a couple visits and, you know, start to understand the value proposition, start to look for patients, and then come online and start prescribing. W e're seeing that really, really week in, week out in terms of that education taking place. Thank you. One moment for our next question. Our next question comes from Eddie Hickman of Guggenheim Securities. Hi, good afternoon, and congrats on the launch so far. Thanks for taking my questions. Just two from me. Can you give any additional color on what went into that 73% gross-to-net discount and how you think that will track over the next few quarters, given it's already better than where we thought it would start? How many of those 1,700 bottles were reimbursed, and how does the limiting sampling work for this product? And then if you can give us sort of any data benchmark on the upcoming MGD study and sort of what you're hoping to see to move forward in that program. Thanks, guys. Hi, it's Jeff. I'll start with the gross to net question. So we did do better than we anticipated. We ended up with an overall gross to net discount of about 73%. I think we were anticipating closer to 80%. The vast majority of that discounting was related to our bridging program, but the delta between our expectations and what we ultimately saw was, you know, a little more coverage than what we were expecting from the commercial side in particular. We do think over time, you know, that as we start to get payer coverage in 2024 with commercial, we'll see that gross to net improve. And then ultimately in 2025, once Medicare comes on, we'll get to a steady state of about 50% gross to net discount. I think the thing we're cautioning folks on, as I mentioned earlier, is in the fourth quarter, now that some of these payers are seeing more scripts come through, they're trying to manage their budgets, you know, if we are not currently contracted with them. W e're anticipating somewhat of a flat, you know, gross-to-net discount from the Q3 because of that. We're starting to see more onerous prior auth. Again, that will be short term, and we do expect to see that improve over time, starting in Q1 of 2024. And then the second question was about the upcoming MGD study. Jeff, do you want to take that one as well? Sure. Yeah. On the MGD study, we anticipate releasing the data here in the next month and a half, prior to year-end. It includes data from two doses, two dose types. One is BID, one is TID, and so we'll be able to release that top-line data sometime later this year. Thank you. Thank you. One moment for our next question. Our next question comes from Oren Livnat of H.C. Wainwright. Thanks. I have a couple questions. Just to revisit this issue of the evolving payer pushback, I guess, in the immediate term. First, can you just help us understand what kind of early experiences you're hearing about physicians having in terms of getting their patient access early on? Do they need to fill out letters of medical necessity now, or is it just going through a specialty pharmacy that's handling all that adjudication for them on the back end so that they don't experience any of that friction per se? And going forward, I guess, obviously, gross-to-net are gonna potentially be volatile, but what about volumes? Do you suspect that if there's an incremental pushback in reaction to your very strong volume out of the gates here, that it could actually get harder? In the near term for someone to get a patient on, and, and what do you have to do to make sure that that doesn't then potentially sour any doctors on the experience going forward? Thanks. Sure, Oren Livnat. I think when you think about that access right now, as Jeff mentioned earlier, through the end of the year, right, we can expect that these folks, as they start to see volume, the payers will put some restrictions in place. We've seen this in pockets. I think that this is something that the doctors can navigate through. The doctors typically initiate the PA, but through our focused pharmacy network, they do get some assistance in that process. But clearly the doctor has to initiate that. They have the patient records. It varies by plan, what the expectations are. I n some cases, a very simple PA. In other cases, we are seeing a little bit more onerous PAs. Mind you, that all this coverage is not contracted right now. So as contracts come online, we would push for a more straightforward PA to label that aligned with a first and only type of product. W e see that evolving over time. In terms of impact to volumes, I think what Jeff is saying is we're continuing to see steady uptake from the physicians. We're seeing that the doctors are getting access to the drug. They're having great success with the drug, so we continue to see that build. I think that you have to just keep in mind that that's more of a headwind. We don't see it as something that would keep the prescription flat, but it does sort of give us a little bit of a headwind as we are building that acceptance with physicians. And I think the doctors are sensitive to that. They know and understand that new products take time to build coverage, and I think it speaks to the value proposition of XDEMVY that people are committed. They're seeing these patients. They don't have another option, so the doctors are putting the effort in, and of course, our programs are there to help that process along. W e think we'll continue to build volume steadily, but certainly, changes in policy or short-term PA adjustments can be a slight headwind as we're ending the year here. Just so I'm clear, where not covered or where pushback is, you know, insurmountable, is that bridging program still getting drug into patients' hands in any and all cases, essentially, such that, you know, we'll continue to see the demand reflected in the prescriptions going forward? It's just a question of the economics that you realize in gross-to-net. That's exactly right, Oren. Perfect. Thanks. I'll get back in the queue. I appreciate it. Thank you. One moment for our next question. Our next question comes from Balaji Prasad of Barclays. Hi, everyone. This is Michaela on for Balaji. Thanks for taking our questions. Just thinking about your pipeline, at what point might you look to expand this further, and are there any areas in particular that would be of interest? Thanks so much. Thank you, Michaela. We do look actively at the entire eye care landscape. As you can imagine, with a great early launch trajectory, with a commercial platform, eventually we want to add more products to our pipeline and to our commercial force. Right now, we can only be so modest, but, you know, we would look to add further products. And so stay tuned. Nothing to report today, but stay tuned. Thank you. One moment for our next question. We have time for one more question. One moment. Our next question comes from Patrick Dolezal of Life Sci Capital. Hi, this is Corey on for Patrick. Thanks for taking our questions. You know, in the call you mentioned that more than 2,000 ECPs have prescribed XDEMVY so far. So it sounds like prescriber adoption has been quite broad as opposed to a really narrow, focused group of prescribers leading most of the volume. Would love to hear more about your strategy and how you've been prioritizing ECP targeting. And I guess also on that note, how are you thinking about marketing in both the near and long term? It seems like marketing has primarily been directed towards prescribers. Can you speak to the relevance of consumer-directed marketing in Demodex blepharitis, and what might your strategy be in that regard? Corey, it's Aziz, and, yeah, no, I think we've been really pleased with the physician acceptance and receptivity. We just came back from both the Academy of Ophthalmology and Academy of Optometry, got a lot of firsthand feedback, so we're real delighted with the uptake we're seeing among the physician community. We're seeing broad updates to your point. And that's been our strategy, right? We didn't want to niche the product. We wanted to go to a broad audience of prescribers. That's why we built the sales force the way we did. We're targeting over 15,000 doctors in our efforts, so we're making great progress in penetrating that marketplace. How we prioritize that is, as I think we've shared before, we take a very data-driven and informed approach. We think about where patient volumes are, we look at claims data, and we look at who has historically been early adopters of other products, and that really helps focus our efforts. We also mentioned earlier that we've already talked to 80% of our top decile doctors, so we've been real thoughtful about where we're deploying the sales force time. I think that the physician receptivity and the number of doctors that have written and repeat written, which is really important, I think reflects that very thoughtful approach. I think in terms of the marketing efforts that you asked about, we've been real intentional here. I think early days, we really have focused on the physician education, building that understanding, that scientific platform, if you will. That will continue to be the focus along with building coverage. The way you can think about it is, once we have great physician penetration, which we're already on a good start on, and as more payer coverage comes in, that's probably gonna signal a great time to think about activating the consumer more purposefully. We do have some consumer education ongoing right now. We've done some smaller campaigns, but in terms of broad-based DTC, which I think you're referring to, I think that comes online when we've got even more adoption among the physician community and even enhanced coverage with our contracts coming online in 2024 and early 2025. Excellent. Thanks for taking our questions, and, congrats on the progress. Thank you. One moment for our last question. This question is from Frank Brisebois of Oppenheimer. Hi, thanks for taking the questions and congrats on the start here. I was just wondering, we talked a little bit in previous questions about optometrists versus ophthalmologists, and I was wondering, can you just help us understand how the pitches are going and the reception is going, between the two different, types of docs? And, you know, if there's any sticky points, or is it, is it a very different pitch between both of them? A ny color on that would be helpful. And then you talked about entering the guidelines here. I was wondering how important that is, for physicians to then prescribe. Thank you. Yeah, Frank, thanks for the question. I think the pitch is very similar overall, right? Our sales messaging is very consistent. You can think about it in really three tranches. We focus on the disease state, building awareness, continuing to promote diagnosis by looking at lids. Secondly, we focus on the value proposition XDEMVY brings, the unique effects that XDEMVY brings across collarettes, mites, and redness. And third, we focus on our pull-through with our pharmacy network, getting the prescription in and the process to get the prescription, which is, of course, really important in early days when we don't have contracts in place. So that's pretty consistent. I think sometimes you do have nuances. Obviously, optometry versus, say, a very busy surgical practice, you do take a slightly different approach. But I think, again, we're seeing great receptivity on both. Again, primary optometry sees a lot of medical visits, so they're incorporating this in. We are hearing from ophthalmologists that they are certainly going to look for a clean, healthy lid before they do a cataract or LASIK surgery. So those things are starting to take hold. And when you think about things like the guidelines, I think that validates the approach, which gives the physicians a lot of confidence. And I think more so, being in those guidelines also helps our discussions with the payers, right? It really positions the product as a standard of care, if you will, in eye care, and I think that helps us in those payer negotiations that are ongoing as well. I think in terms of the day-to-day feedback, I've been out in the field, I'm hearing that personally. I know, Bobby, you mentioned you've been out in the field. Maybe you have a couple other insights to offer as well here. Yeah. I would just add, I mean, we came back from both major academies, optometry and ophthalmology, in the last several weeks, and, the value proposition is very strong. Whether it was at our booth or in advisory boards for commercial or medical affairs, there's tremendous interest. And I think as you're seeing in the data, there is a little more demand from optometry out of the gate. They've been already looking at the list, probably a little bit more than the ophthalmologist. But we know how collaborative these doctors work together. So when we talk about that hybrid approach, it's really because in a given clinic, you'll see optometrists and ophthalmologists working together. That was very striking to me, being out in the field. And then there was one question about guidelines. I think you had, Frank. Did you wanna cover that, Aziz? Yeah. I think, what we said on the guidelines- Yeah. was that, you know, I think that's important validation for the physician, but again, I think really does validate for the payers as well. W e're delighted. I think we anticipate, you know, incorporating in other guidelines as well. But the AAO practice patterns, I think, are really important. I mean, I think just for reference to add to that is, those aren't updated very often, right? Those are updated every handful of years. T o be included this year right after launch is a, is a real testament to the medical efforts that we had, the scientific platform we've had out there, and I think is reflected in that. Thank you. Thank you, Frank. Thank you. This concludes the Q&A session. I would like to now turn it back to Bobby Azamian for closing remarks. Thank you all again for your time and interest. We really look forward to keeping you updated on our progress as we work diligently to deliver on the promise of XDEMVY. Hope everyone has a great day. This concludes today's conference call. Thank you for participating, and you may now disconnect.